TMO Thermo Fisher Scientific Dashboard

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Its Mission is to enable our customers to make the world healthier, cleaner and safer. Whether the customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, the company is here to support them. Its global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Company profile

Ticker

TMO

Exchange

NYSE

Website

www.thermofisher.com

CEO

Marc Casper

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Testing Laboratories

Industry (SIC)

Measuring & Controlling Devices, NEC

Rockwell Automation • Trimble • Cubic • MTS Systems • Faro • Onto Innovation • Owlet • Geospace Technologies • 908 Devices • Autoscope Technologies ...

Former names

THERMO ELECTRON CORP

SEC CIK

0000097745

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Thermo Fisher Scientific Operating Company LLC • Thermo Fisher Scientific Senior Financing LLC • Thermo Fisher Scientific (DE) Holding S.a.r.l. • Laboratory Management Systems, Inc. • Thermo Fisher Scientific Peru S.R.L. • Thermo Fisher Scientific Malaysia Sdn. Bhd. • Thermo Fisher Scientific (Barbados) Holding, Limited • Fisher Clinical Logistics LLC • Fisher Clinical Services (Suzhou) Co., Ltd. • Fisher Clinical Services Limited Liability Company ...

IRS number

42209186

TMO stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Clever Culture Systems Selects Thermo Fisher Scientific as Exclusive US APAS Distributor

27 Sep 21

Australian medical technology company LBT Innovations Limited (ASX: LBT) is pleased to announce the signing of an exclusive Distribution Agreement for the APAS® Independence in the United States (the Agreement) with Remel Inc., a part of Thermo Fisher Scientific, Inc. (Thermo Fisher). Key Points:

Semiconductor Shortage Hits Supply Chain For MedTech Industry

24 Sep 21

FDA Establishes Additional Conditions Of Emergency Use Nod For COVID-19 Tests For Viral Mutations

24 Sep 21

The FDA has issued a letter to establish additional conditions of Emergency Use Authorizations (EUAs) manufacturers of COVID-19 tests.

Thermo Fisher Scientific Authorizes $3 Billion of Share Repurchases

23 Sep 21

'Fast Money Halftime Report' Picks For September 23

23 Sep 21

Press releases

Pro users get this 30m faster

Thermo Fisher Scientific Authorizes $3 Billion of Share Repurchases

23 Sep 21

WALTHAM, Mass., Sept. 23, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its board of directors has authorized the repurchase of $3 billion of

Thermo Fisher Scientific to Present at the JP Morgan 12th Annual U.S. All Stars Conference on September 22, 2021

21 Sep 21

WALTHAM, Mass., Sept. 21, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present

Thinking about trading options or stock in AMC Entertainment, Plug Power, Palantir Technologies, Advanced Micro Devices, or Thermo Fisher Scientific?

20 Sep 21

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, PLUG, PLTR, AMD, and TMO.

Thermo Fisher Scientific to Host Virtual Investor Day

9 Sep 21

Thermo Fisher Scientific Awarded $192.5 Million U.S. Government Contract to Expand Domestic Pipette Tip Manufacturing

2 Sep 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

6 Aug 21

28 Sep 21

31 Dec 21

Financial summary

Financial statements Chart TMO financial data

Quarter (USD)	Jul 21	Apr 21	Dec 20	Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Recent insider trades

TMO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Aug 21	Casper Marc N	Common Stock	Other	Acquire J	Yes	No	0	89,155	0	89,155
27 Aug 21	Casper Marc N	Common Stock	Other	Dispose J	Yes	No	0	34,825	0	0
27 Aug 21	Casper Marc N	Common Stock	Other	Dispose J	Yes	No	0	54,330	0	0
27 Aug 21	Casper Marc N	Common Stock	Payment of exercise	Dispose F	No	No	548.51	2,528	1.39M	182,174.53
27 Aug 21	Boxer Michael A	Common Stock	Payment of exercise	Dispose F	No	No	548.51	160	87.76K	10,918
27 Aug 21	Joseph R. Holmes	Common Stock	Payment of exercise	Dispose F	No	No	548.51	16	8.78K	851
27 Aug 21	Michel Lagarde	Common Stock	Payment of exercise	Dispose F	No	No	548.51	293	160.71K	16,879.205
27 Aug 21	Mark Stevenson	Common Stock	Payment of exercise	Dispose F	No	No	548.51	1,158	635.17K	59,256
26 Aug 21	Casper Marc N	Common Stock	Payment of exercise	Dispose F	No	No	552.77	2,302	1.27M	184,702.53
26 Aug 21	Boxer Michael A	Common Stock	Payment of exercise	Dispose F	No	No	552.77	240	132.66K	11,078

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q2 2021

TMO institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

85.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2013	1987	+1.3%
Opened positions	146	139	+5.0%
Closed positions	120	137	-12.4%
Increased positions	827	810	+2.1%
Reduced positions	725	744	-2.6%

13F shares	Current	Prev Q	Change
Total value	169.44B	153.9B	+10.1%
Total shares	335.91M	337.28M	-0.4%
Total puts	2.13M	1.73M	+23.1%
Total calls	1.96M	2.51M	-21.9%
Total put/call ratio	1.1	0.7	+57.7%

Largest owners	Shares	Value	Change
Vanguard	30.71M	$15.49B	-0.4%
BLK Blackrock	28.75M	$14.51B	-1.9%
STT State Street	15.55M	$7.85B	+2.1%
Capital World Investors	14.77M	$7.45B	-11.8%
TROW T. Rowe Price	13.32M	$6.72B	+19.1%
Massachusetts Financial Services	12.03M	$6.07B	-2.2%
FMR	10.13M	$5.11B	-15.4%
Capital Research Global Investors	9.06M	$4.57B	+2.3%
MS Morgan Stanley	8.31M	$4.19B	+0.2%
Geode Capital Management	6.07M	$3.05B	+2.9%

Largest transactions	Shares	Bought/sold	Change
TROW T. Rowe Price	13.32M	+2.13M	+19.1%
Amundi Pioneer Asset Management	0	-2.13M	EXIT
Capital World Investors	14.77M	-1.97M	-11.8%
FMR	10.13M	-1.84M	-15.4%
Amundi	1.77M	+1.77M	NEW
Wellington Management	4.14M	-1.03M	-19.9%
HBCYF HSBC	1.82M	+997.95K	+121.6%
IVZ Invesco	1.44M	-907.79K	-38.6%
Generation Investment Management	1.71M	+688.02K	+67.6%
Putnam Investments	1.11M	+670.37K	+152.7%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Bio-Rad Laboratories • Quidel • Mesa Laboratories • Accelerate Diagnostics • Waters • Luminex • Biocept • Reflect Scientific • Illumina • Harvard Bioscience

Management Discussion

Sales in the second quarter of 2021 increased $2.36 billion from the second quarter of 2020. Aside from the effects of currency translation and acquisitions, revenues increased $1.92 billion (28%) primarily due to increased demand. Sales of products that address COVID-19 testing and treatment increased $0.58 billion to $1.87 billion in the second quarter of 2021. Conditions were very robust in each of the company’s end markets during the second quarter of 2021 driven by three factors: strong fundamentals in the life sciences, strong economic activity globally and the role the industry is playing in the pandemic response. Sales were particularly strong to academic and government, as well as industrial and applied customers, which were most affected in the second quarter of 2020 due to business disruptions related to the pandemic. Sales to customers in pharma and biotech markets were very strong driven by underlying market dynamics and the company’s role in supporting customers across a wide range of therapeutic areas. Sales to customers in diagnostics and healthcare markets were strong as customer demand for non-COVID-19 response products and services was approaching pre-pandemic levels. Sales growth was strong in each of the company’s primary geographic areas during the second quarter of 2021.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: approaching, behalf, certification, compensatory, copy, digital, document, documentary, duly, embedded, Exhibit, formatted, FTC, furnish, HSR, Inline, instance, Joseph, Label, lessened, Linkbase, merger, playing, proposed, request, Restated, role, Schema, Taxonomy, therapeutic, thereunto, undersigned, waiting, XBRL

Removed: accelerated, continuing, diagnosing, focused, number, past

From filing 10-Q 2021 Q2